Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 1999

View Archived Issues

York Medical: Annual Report 1998

U.S. patent issues to Washington University for mammaglobin

Steroidogenesis Inhibitors to begin satellite open clinical studies in multiple indications

Synvisc relieves pain, delays need for total knee replacement in osteoarthritis

Cubist enters agreement with Novartis for antiinfective drug discovery

Pierre Fabre Dermatologie to commercialize Allergan's Zorac in Europe

Positive preclinical results for NuChem's anticancer compounds in lung cancer model

InSite Vision updates shareholders

PSP94 suppresses prostate cancer growth in mouse model

Rosetta and Acacia announce intention to merge

Abbott makes milestone payments to Aronex for antifungal drug Nyotran

Orally bioavailable tachykinin antagonists from MS&D for emesis, etc.

Biota's flu drug gets first approval

Astra describes N-type neuronal calcium channel blockers and their use

Good safety, increased immunogenicity reported for MF59-adjuvanted flu vaccine

Neurogen and Pfizer collaborate on development of NPY receptor ligands

New antiinflammatory/immunomodulatory compounds from Signal act at a transcriptional level

New compounds from Novo Nordisk for pain, inflammation, diabetes

Kanebo to be acquired by Organon, merged into Nippon Organon

Mitsubishi antidepressant to be codeveloped by Taisho

Glaxo presents new NNRTI from quinoxaline class that has progressed to human trials

T-140, a potent CXCR4-dependent inhibitor of HIV infection

Pediatric study supports use of vCP205 in infants born to HIV-positive mothers

Bristol-Myers Squibb suspends clinical studies of lobucavir

Celebrex receives approval in Mexico

Broad patent issues for Avigen's AAV vectors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...